Riskpilot← Back to searchSign inGet full accessEfarmogi AB
ABActiveOrg 5592688989Sandgärdsgatan 16Restaurant activities · NACE 5611Est. 202020-49 employees
Revenue 2025
SEK 5,9M
+417% vs 2024
EBITDA margin
6.1%
+481% vs 2024
Equity ratio
9.1%
Financial strength
Net profit 2025
SEK 253K
+362% vs 2024
| Revenue | SEK 5,9M | +417% |
| EBITDA | SEK 359K | +481% |
| Net profit | SEK 253K | +362% |
| Total assets | SEK 2M | +212% |
| Equity | SEK 182K | +354% |
| Employees | — | — |
Legal name
Efarmogi AB
Org number
5592688989
Legal form
Aktiebolag
NACE code
5611 · Restaurant activities
Founded
28 augusti 2020
Share capital
SEK 25 000
Employees
20-49
VAT registered
Yes
Audit selected
No
Last report
2025-03-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Aktiebolaget är inriktat på att vara restaurang, bar och café med inomhus- och utomhusservering.
Address
Sandgärdsgatan 16
Email
ramiatou89@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1 133 | 5 860 |
| Staff expenses | — | — | — | −537 | −2 169 |
| EBITDA | — | — | — | −94 | 359 |
| Depreciation & amort. | −0 | −0 | −0 | −1 | −14 |
| EBIT | 0 | 0 | 0 | −95 | 345 |
| Net financials | — | — | — | −2 | −45 |
| Profit before tax | 0 | 0 | 0 | −97 | 301 |
| Tax | −0 | −0 | −0 | — | −48 |
| Net profit | 0 | 0 | 0 | −97 | 253 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 25 | 25 | 25 | 640 | 1 993 |
| Equity | 25 | 25 | 25 | −72 | 182 |
| Long-term debt | 0 | 0 | 0 | — | — |
| Short-term debt | 0 | 0 | 0 | 711 | 1 812 |
| Total debt | — | — | — | 711 | 1 812 |
EBITDA margin
6.1%
This company
15.8%
Market median
-61% vs market
20212025
Equity ratio
9.1%
This company
38.2%
Market median
-76% vs market
20212025
Return on equity
139.4%
This company
18.4%
Market median
+658% vs market
20212025
Net profit margin
4.3%
This company
8.1%
Market median
-47% vs market
20212025
Asset turnover
2.94×
This company
1.12×
Market median
+162% vs market
20212025
Debt / equity
9.98×
This company
0.62×
Market median
-1510% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-04-01 – 2022-03-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-08-01 – 2021-03-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2025 | |
| Deputy Board Member | 2025 | |
| Former (6) | ||
| Board of Directors | 2024 – 2025 | |
| Deputy Board Member | 2023 – 2023 | |
| Chairman | 2023 – 2023 | |
| Deputy Board Member | 2022 – 2024 | |
| Board of Directors | 2022 – 2024 | |
| Deputy Board Member | 2024 – 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Efarmogi AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Omar Elias | Board of Directors | 0 companies |
| Lisa Astha Matilda Elmersson | Deputy Board Member | 0 companies |
| Julien Anastazy Papadopulos | Chairman | 0 companies |
| Cristina Torres Sandoval | Deputy Board Member | 0 companies |
| Paraschos Skarlatos | Board of Directors | 0 companies |
| Janet Atto Al-Khalaf | Deputy Board Member | 0 companies |
| Rami Atou Al-Khalaf | Board of Directors | 0 companies |
| Vivian Sharmeen Shekh | Deputy Board Member | 0 companies |